-
August 06, 2012
New York, August 6th (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) are trading
very close to ...
-
August 03, 2012
Like so many people around the planet, I tuned into some Olympic action over the weekend. Ever since childhood, I ...
-
July 27, 2012
MoneyShow's Tom Aspray takes an in-depth look at his successful Charts in Play Portfolio, as he looks to take ...
-
July 27, 2012
Amgen (AMGN) continued its strong performance in 2012 with second quarter earnings coming in at $1.82 per share, 31 ...
-
July 26, 2012
Amgen (Nasdaq:AMGN) announced its results for the most recent quarter on July 26, 2012. Amgen is a biotechnology ...
-
July 24, 2012
Amgen (Nasdaq:AMGN) will release its second quarter results on Thursday, July 26, 2012. Analysts are expecting the ...
-
July 23, 2012
New York, July 23rd (TradersHuddle.com) - Shares of Amgen Inc. (NASDAQ:AMGN) are trading
very close to ...
-
July 16, 2012
Celgene Corporation (CELG) recently announced positive top-line results on its candidate apremilast from a phase III ...
-
July 13, 2012
Merck (MRK) recently received good news on the pipeline front with the Data Monitoring Committee (DMC) for its ...
-
July 10, 2012
Merck KGaA (MKGAF) recently announced that Erbitux failed to achieve its primary endpoint in the phase III EXPAND ...
-
July 09, 2012
Amgen (AMGN) recently completed its acquisition of privately held pharma company, KAI Pharmaceuticals. With this ...
-
July 09, 2012
Bristol-Myers Squibb Company (BMY) and partner Eli Lilly & Company (LLY) recently announced that they have received ...
-
July 06, 2012
Recently, DaVita Inc. (DVA) agreed to pay $55 million in a bid to settle a lawsuit, indicting it for overuse of ...
-
June 11, 2012
Amgen (AMGN) recently reported disappointing results on Sensipar (EU trade name: Mimpara) from a phase III study - ...
-
June 08, 2012
Dr. Reddy's Laboratories Ltd. (RDY) recently announced a collaboration agreement with Merck Serono, a division of ...
-
June 07, 2012
Abbott Labs (ABT) recently presented phase III data on its blockbuster drug, Humira, from two studies. While ...
-
May 22, 2012
Agilent is paying up to get into the increasingly crowded diagnostics market.
-
May 17, 2012
Biotech ETFs are hitting all-time highs and XBI looks like the best of the group. Because the ETF is already up 25% ...
-
May 03, 2012
AstraZeneca has an opportunity to do something big when it brings in a new CEO.
-
April 13, 2012
The lack of real trend confirmation helped Jeff White stay on the sidelines for these three stock set-ups gone bad, ...
